Epitelijski rak jajčnikov, rak jajcevodov, primarni peritonealni serozni karcinom (PPSC) Epithelial ovarian cancer, fallopian tube cancer, primary peritoneal serous cancer (PPSC)

systemic treatment recommendations

Abstract

Ni abstrakta.

Abstract (Eng)

Epithelial ovarian cancer is known to be one of the most sensitive to systemic treatment with chemotherapy. Objective response to treatment was achieved in more than 80% of patients. Therefore, chemotherapy treatment is a standard part of primary treatment after completed surgery (adjuvant treatment). If surgical treatment is not possible, patients begin treatment with preoperative (neoadjuvant) chemotherapy, which is followed by surgery. In primary systemic treatment, we have been using chemotherapy in combination with taxanes and platinum-based preparations. In systemic treatment of fallopian tube cancer, we also use – besides chemotherapy – bevacizumab, an inhibitor of the vascular endothelial growth factor (VEGF). Systemic treatment presents the principal treatment also in disease recurrence. The type of systemic treatment in disease recurrence depends on the time elapsed since the end of primary treatment until recurrence. In the last couple of years, we have been again witnessing the introduction of new medicines for treatment of patients with fallopian tube cancer. For this reason, the Institute of Oncology Ljubljana this year updated its guidelines for systemic treatment of epithelial ovarian cancer. In this paper, we present the current recommendations for systemic treatment of epithelial ovarian cancer in Slovenia. Epithelial ovarian cancer, fallopian tube cancer and primary peritoneal serous cancer (PPSC) have the same clinical course and the same systemic treatment, therefore they are all managed in the same manner.